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Abstract Inhalation anthrax has a rapid progression and high
fatality rate. Pathology and death from inhalation of Bacillus
anthracis spores are attributed to the actions of secreted pro-
tein toxins. Protective antigen (PA) binds and imports the cat-
alytic component lethal factor (LF), a zinc endoprotease, and
edema factor (EF), an adenylyl cyclase, into susceptible cells.
PA-LF is termed lethal toxin (LTx) and PA-EF, edema toxin.
As the universal transporter for both toxins, PA is an important
target for vaccination and immunotherapeutic intervention.
However, its quantification has been limited to methods of
relatively low analytic sensitivity. Quantification of LTx may
bemore clinically relevant than LF or PA alone because LTx is
the toxic form that acts on cells. A method was developed for
LTx-specific quantification in plasma using anti-PA IgG mag-
netic immunoprecipitation of PA and quantification of LF ac-
tivity that co-purified with PA. Themethodwas fast (<4 h total
time to detection), sensitive at 0.033 ng/mL LTx in plasma for
the fast analysis (0.0075 ng/mL LTx in plasma for an 18 h
reaction), precise (6.3–9.9 % coefficient of variation), and
accurate (0.1–12.7 %error; n≥25). Diagnostic sensitivity
was 100 % (n=27 animal/clinical cases). Diagnostic specific-
ity was 100 % (n=141). LTx was detected post-antibiotic
treatment in 6/6 treated rhesus macaques and 3/3 clinical cases
of inhalation anthrax and as long as 8 days post-treatment.
Over the course of infection in two rhesus macaques, LTx
was first detected at 0.101 and 0.237 ng/mL at 36 h post-
exposure and increased to 1147 and 12,107 ng/mL in late-
stage anthrax. This demonstrated the importance of LTx as a
diagnostic and therapeutic target. This method provides a sen-
sitive, accurate tool for anthrax toxin detection and evaluation
of PA-directed therapeutics.
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Introduction
Bacillus anthracis produces two binary toxins associated with
the pathogenesis of anthrax [1]. Protective antigen (PA) is an
83-kDa protein responsible for cell binding and target cell
translocation of catalytic toxin components lethal factor (LF)
and edema factor (EF). Thus, PA is the universal target for
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development of anti-toxin treatments and vaccines since
blocking it prevents cellular intoxication. Methods described
for detecting PA include ELISA, europium nanoparticle-based
immunoassay, time-resolved fluorescence immunoassay [2–5],
electro-chemiluminescence, metal-enhanced fluorescence,
AlphaLISA, and surface plasmon resonance [6–9]. However,
these methods can be lacking in precision, sensitivity, and
quantitative accuracy, and in some, their utility has not been
verified by matrix testing or application to infection samples.
Detection of PA during infection can be complex as it may
exist in many forms. During cellular intoxication, PA83 binds
to cell surface receptors CMG2 and TEM8 [10, 11], where it is
cleaved by furin-like proteases, releasing its 20-kDa amino
terminus, leaving 63 kDa (PA63) bound to the cell surface
[1]. PA63 forms heptameric and octameric complexes [12,
13], which are capable of binding up to four molecules of
the catalytic toxin components, edema factor (EF), and lethal
factor (LF) [13, 14]. EF bound to PA is described as edema
toxin and LF bound to PA as lethal toxin (LTx). The PA63-EF/
LF complexes are internalized by clathrin-mediated endocy-
tosis [15]. The low pH within the endosome triggers confor-
mational changes in the PA63 oligomer, leading to pore-
formation and translocation of EF/LF into the cell cytoplasm
[1]. Within the cell, EF, an adenylate cyclase and LF, a zinc-
dependent endoproteinase cause irreversible changes in their
known substrates, adenosine tri-phosphate and mitogen-
activated protein kinase (MAPKK), respectively [16, 17].
Previous studies found that PA83 is activated to PA63 by
proteases in the blood [18, 19]. Serum protease-activated
PA63 was shown to bind LF and form fully functional LTx
[20]. LTx was also identified in terminal blood of infected
rabbits and guinea pigs [20]. None of the PA was found as
PA83 [18, 20]. These findings suggest LTx is a potential di-
agnostic biomarker and distinct therapeutic target. However,
LTx has not been detected or measured prior to the moribund
and terminal stages. Thus, until this work, it was not known
whether LTx is present in early infection.
We previously described an isotope-dilution (ID) matrix-
assisted laser-desorption ionization time-of-flight (MALDI-
TOF) mass spectrometry method that quantifies total LF (free
LF+LTx) [21]. The method incorporates three steps, antibody
capture, LF peptide substrate cleavage, and MS detection of
cleaved peptide. These steps each provide a level of specificity
and sensitivity and matrix detection limits of 0.005 pg/mL
[21–24].
The utility of total LF measurement was demonstrated in
two circumstances. The first was characterization of triphasic
toxemia during the course of experimental inhalation anthrax
[25]. The second was characterization of toxin clearance dur-
ing treatment of naturally occurring inhalation anthrax which
showed that total LF declined gradually with antibiotic treat-
ment and rapidly with anthrax immune globulin intravenous
(AIGIV) anti-toxin treatment [26, 27]. AIGIV is composed of
immune plasma from individuals immunized with the anthrax
vaccine adsorbed (BioThrax®) [28]. The therapeutic compo-
nent is predominantly anti-PA IgG which binds PA and asso-
ciated proteins such as LF and EF, targeting them for removal
from circulation through Fc-mediated immune mechanisms.
Monitoring LF provides an indirect measurement of toxin
clearance since it is not known howmuch LF is PA associated.
An LTx-specific method would provide a direct measure of
PA-specific toxin clearance. Importantly, it could also deter-
mine the presence of LTx throughout infection and its poten-
tial as a therapeutic and diagnostic target.
Here, we describe a three-step method to detect and mea-
sure LTx. Anti-PA mAb magnetic beads were used to immu-
noprecipitate PA (Fig. 1, step 1). Immobilized LTx is reacted
Fig. 1 Schematic of the three-step LTx method. LTx-specific activity is
analyzed using anti-PAmAb's onmagnetic beads to capture LTx complex
(step 1) followed by incubation of LTx on the bead with a MAPKK-like
peptide substrate which it hydrolyzes into two distinct smaller peptide
products (step 2). The products are detected and quantified by isotope-
dilution MALDI-TOF MS for a measure of the LTx in a sample (step 3)
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with and hydrolyzes an optimized peptide substrate
(step 2). Cleaved peptide products are detected and
quantified by MALDI-TOF MS (step 3). This provided
measurement of LF that co-purified with activated
PA63, quantifying LTx complex. This study describes
development, validation, and application of the LTx
method. The method was sensitive, specific, and precise
and demonstrated for the first time that PA63 as LTx is
present in early anthrax.
Materials and methods
Reagents
Materials and reagents were obtained from Sigma-Aldrich (St
Charles, MO) except where indicated. LF, EF, PA83, and
PA63 were obtained from List Biological Laboratories
(Campbell, CA). Normal North American (NNA) human
ten-donor-pooled plasma and serum and plasma from 100
individual NNA donors were obtained from Interstate Blood
Bank (Memphis, TN). AIGIV was obtained from the Division
of Strategic National Stockpile, CDC (Atlanta, GA).
Animal care and study protocol
The inhalation anthrax study in 24 rhesus macaques (Macaca
mulatta) was conducted at the Battelle Biomedical Research
Center (Columbus, OH) as previously described and approved
by both Battelle and the Centers for Disease Control and Pre-
vention Institutional Animal Care and Use Committees [25].
This two-part study was approved in 2006 (CDC IACUC
protocol no. 1459BOYMONX and Battelle MREF protocol
no. 570) and carried out in 2006–2007. Sufficient sample vol-
umes generated from this approved protocol were remaining
and used for this study. Animals were challenged with 275±
72 LD50 aerosolized B. anthracis Ames spores by inhalation
(target dose 200 LD50). Whole blood and plasma were col-
lected in EDTA tubes at −30 days and 12, 18, 24, 36, 48, 72,
96, and 120 h, and serum was collected for five animals as
described previously [25]. Plasma/serum was filter sterilized
and culture confirmed before shipment. Culture and PCR of
the protective antigen gene (pagA) were described previously
[25]. Total LF and LTx analysis was determined in two ani-
mals, 16N and 89N, over the course of infection. An addition-
al 22 post-spore exposure samples were analyzed. Pre- and
post-antibiotic treatment samples were available for six ani-
mals treated with Ciprofloxacin at 20 mg/kg twice daily for
14 days in surviving animals. Treatment commenced at 48 h
post-challenge in four animals and at 72 h in two. Four of six
survived.
Magnetic antibody beads
Anti-PA mouse monoclonal antibodies (mAb) AVR1046 and
two anti-LF mAb (AVR1674 and AVR1675) were linked to
Tosyl-activated magnetic beads (MB; Life Technologies,
Grand Island, NY) according to the manufacturer’s instruc-
tions yielding anti-PA and dual anti-LF MBs. Kingfisher 96
magnetic particle processor (Thermo-Fisher Scientific,
Waltham, MA) was used for all MB handling.
Antibody specificity
Specificity of anti-PA and anti-LF MBs was demonstrated for
LTx, LF, and PA. PA63/LF were mixed at a w/w ratio of 10:1
to form LTx complex. PA83 and LF were mixed as a non-
complexed control. Mixtures were incubated at room temper-
ature (RT) for 30 min. LF, PA63, PA83, LF/PA63, and LF/
PA83 at 0.5 μg LF and 5 μg PA83 or PA63 were
immunoprecipitated with anti-LF and anti-PA MBs, eluted
with 50 % acetonitrile, 2 mM HCl for 1 min, dried by centrif-
ugal evaporation, reconstituted in sample buffer, analyzed by
5–14% SDS-polyacrylamide gel electrophoresis (PAGE; Life
Technologies), and visualized by silver stain (SS; Protea Bio-
sciences, Morgantown, WV).
Lethal toxin standard preparation and characterization
LTx was formed by mixing PA63 and LF at w/w ratios of 0:1
to 60:1 PA63/LF, incubating at RT for 30 min. Mixtures were
analyzed for free LF levels by non-denaturing PAGE (Life
Tech) and SS. A ratio of 50:1 adsorbed the maximum amount
of LF. The final LTx standard material was similarly prepared
with 25 μg PA63/0.5 μg LF for 500 ng/μL PA63 and 10 ng/
μL LF as LTx, then diluted as described below to make stan-
dard and quality control materials.
The LTx standardmaterial was analyzed by non-denaturing
PAGE to quantify the Bfree^ LF and correct standards. Gel
lanes contained 7.5 μg PA63, 25, 12.5, 6.25, and 3.125 ng LF
and the LTx standard material with 150 ng LF and 7.5 μg
PA63 to visualize and quantify the small amount of unbound
LF. The gel was scanned and bands intensities quantified
(Softmax Pro, Molecular Devices, Sunnydale, CA). Free LF
intensities were fitted to a linear regression (r2=0.996), and
free LF in the LTx lane was calculated from the linear
regression.
The qualitative efficiency of anti-PA purification of the LTx
standardmaterial in plasma in the presence of the excess PA63
was determined by comparison with anti-LF purifica-
tion. The LTx standard material at 100, 50, 25, and
12.5 ng LF and 50 times PA63 each in plasma sample were
immunoprecipitated by anti-PA and anti-LF MBs and eluted
and analyzed by SDS-PAGE/SS.
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Standard and quality control (QC)materials in plasmawere
prepared from the characterized material with free LF
corrected values of 24.3 to 0.0025 ng/mL and three QCs with
5.82 ng/mL (QCH), 0.582 ng/mL (QCM), and 0.0582 ng/mL
(QCL) LTx.
LTx quantification
For LTx analysis, 50 μL of sample was diluted 1:10 in 450 μL
phosphate-buffered saline with 0.05 % Tween20 (PBST),
mixed with 6.25 μL anti-PA-MBs for 1 h, washed two times
2 min each in 1.0 mL PBST, then in 200 and 100 μL dH2O for
1 min each, resuspended in 30 μL reaction buffer with the
peptide substrate and reacted for 2 and 18 h at 37 °C. After
the 2-h reaction, 3 μL of sample was mixed with α-cyano-4-
hydroxycinnamic acid (CHCA) at 5 mg/mL in 50 % acetoni-
trile, 0.1 % trifluoroacetic acid, and 1 mM ammonium phos-
phate (CHCA-MALDI matrix) and isotopic internal standard
peptides (ISTD) and analyzed by ID-MALDI-TOF/MS as de-
scribed previously [22, 23]. The remaining reaction was incu-
bated for analysis at 18 h. The LTx cleaved peptide MS peak
area/ISTD peak area (area ratio) was plotted versus LTx stan-
dard concentration with dual log10 transformation and 5PL
robust quantification.
LTx method validation
Recovery for this method compared activities for 0.5 ng LF
and LTx (0.5 ng LF+1 ng PA63) both without capture and
with anti-PA purification. Precision, accuracy, and LOD were
determined from 25 standards/QC analyses with precision as
the coefficient of variation (%CV) and accuracy as the percent
error (%error). Acceptable criteria described previously [29]
place accuracy at ≤20 % error and precision at ≤20 %CV
except at the upper (≤15 %) and lower limit of quantitation
(<25 %). Linearity was acceptable with a slope ≥0.8 and ≤1.2
and an r-squared ≥0.85. Quantifiable ranges were determined
using these criteria for both 2- and 18-h reactions. Limits of
detection (LOD) were determined for the method including all
steps (sample preparation, enzymatic reaction, and MALDI-
TOF analysis) by plotting standard deviations (SD) versus
concentration for the plasma blank and three low standards,
one above, one near, and one below the estimated LOD for 30
runs. The y-intercept and slope from the linear regression, the
SD, and mean of the blank (SDb and meanb) were used to
calculate the LOD concentration as follows [30]:
ConcLOD ¼ meanb þ 1:645 sb þ intð Þð Þ
.
1−1:645 slopeð Þð Þ
where b is blank, s is standard deviation, and int is y-intercept.
Specificity was assessed from 100 individual NNA plasma
samples and 41 archived human serum samples that included
elderly Argentinian’s, children from San Diego without
routine immunizations, and other infections (Staphylococcus
aureus , Legionella pneumophila , Chlamydophila
pneumoniae). Sensitivity was assessed for samples from 24
rhesus macaques (19 plasma collected, 5 serum collected)
with inhalation anthrax, and in samples from three inhalation
anthrax cases (CDC IRB Protocol no. 5343.0, Use of Residual
Human Specimens for Laboratory Diagnostic Research) [26,
27, 31]. Samples were analyzed with two or more replicates at
one or more dilutions for both 2- and 18-h reactions. Lower-
level samples requiring higher sample volumes were analyzed
singly due to limited sample volumes. For these, means were
from both 2- and 18-h results.
Accuracy was assessed for plasma samples with 7.5, 0.75,
and 0.075 ng/mL LTx co-spiked with PA83, LF, and EF at
50 ng/mL each, analyzed in triplicate. For matrix accuracy,
serum and plasma from five individual donors each were
spiked with LTx at 2.5 ng/mL and analyzed in duplicate.
Matrix-dependent activation of PA83 to PA63 and formation
of LTx was assessed using ten-donor pooled serum and plas-
ma spiked with either 5 ng/mL PA83 or PA63 and then 2.5 ng/
mL LF, incubated for 1 h then analyzed for LTx.
For utility with anthrax therapeutics, AIG interference was
assessed by spiking AIG at an equivalent of 200 μg/mL anti-
PA IgG into all 15 standards, plasma blank, and QC samples
over the entire range from 24.3 to 0.0024 ng/mL. These were
prepared, spiked, and analyzed, on two separate days along-
side control (no AIG) standards/blank/QCs spiked with PBS
instead of AIG. A clinical anthrax sample with previously
quantified LTx of 88 ng/mL was analyzed in triplicate without
and with AIG spiked at 200 μg/mL anti-PA IgG. After spik-
ing, samples were mixed for 1 h then analyzed for LTx. Inter-
ferences from antimicrobial treatment were assessed by ana-
lyzing LTx before and after treatment for animal and clinical
inhalation anthrax described above.
Data reporting and statistical analyses
Analyses and formulas were described above where appropri-
ate. Standard calculations, means, standard deviations, and
linear regressions were performed in excel. Custom visual
basic programs calculated values for LTx from the 5PL regres-
sions. LTx levels were reported in nanograms per milliliter.
Grading for culture results were described previously [25].
Results
Method overview
As described in the BIntroduction,^ the method has three pri-
mary steps, magnetic immunoprecipitation, substrate cleavage
reaction, and MALDI-TOF MS quantification. The following
results include characterization of LTx complex formation
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from PA63 and LF for standards material, characterization of
the ability of the magnetic-bead-coated antibodies to selec-
tively purify LTx, LTx reaction with substrate, and MALDI-
TOF MS quantification of LTx reaction products.
LTx standard preparation and characterization
Since the measurement of LTx relies on detection of LF ac-
tivity in LTx complex, the aim was to create standards with a
minimum of free LF. Activated PA63 exists as a heptamer/
octamer that binds up to four LF molecules forming the LTx
complex, with optimal molecular ratios represented by a
weight/weight ratio of 1.5:1 PA63/LF [12, 13, 32]. However,
optimum binding of LF in these standards materials required
50:1 PA63/LF as visualized by non-denaturing gel electropho-
resis and higher PA63 levels did not bind more LF (not
shown). PA63 alone with multimer and monomer (Fig. 2a,
lane 1) was compared with the LTx mixture (lane 6) which
shows two additional primary bands that migrate lower than
the non-complexed multimer. These bands represent the LTx
complex. A significant amount of PA63 multimer and mono-
mer remains uncomplexed. The free LF band in lane 6 was
visible, and its gel-band intensity was quantified against a
linear regression derived from the LF-only lanes 2–5. The
amount of free LF in the standards was quantified at
4.56 ng, which was 3 % of the total 150 ng LF loaded
(Fig. 2a). LTx standard concentrations were corrected by
subtracting the 3 % free LF.
Magnetic antibody bead specificity
Antibody specificities demonstrated bymagnetic immunoprecip-
itation of individual toxin components showed that anti-LF pu-
rified LF but not PA83 or PA63 and anti-PA purified PA83 and
PA63 but not LF (Fig. 2b). Specificity for pre-formed LTx com-
plex was observed for both anti-PA and anti-LF since both PA63
and LF bands were extracted and present (Fig. 2c). With PA83+
LF, complex was not formed and anti-LF extracted LF but not
PA83 and anti-PA extracted PA83 but not LF. In all, the data
support the individual specificities of anti-PA and anti-LF mAbs
for LF and PA and the ability of both to purify LTx complex.
Since LTx standards were prepared with 50 times more
PA63 than LF, it was determined whether the excess PA63
interfered with purification of LTx. Immunoprecipitation of
100 to 12.5 ng LTx standard material from plasma showed
that the amount of LF in complex extracted by anti-PA and
anti-LF MBs were visually similar (Fig. 2d). Additionally, the
PA63 bands purified by anti-PA were more intense (lanes 5–
Fig. 2 LTx and antibody characterization. LTx for standard material was
analyzed by non-denaturing gel electrophoresis. The gel was scanned, LF
band intensities were quantified, and the amount of free LF was estimated
from the linear curve (a). Specificity of anti-LF and anti-PA for LF, PA83,
and PA63 alone (b), PA63/LF (LTx) and PA83/LF (c), and LTx standards
material; A 100 ng LTx, B 50 ng, C 25 ng, and D 12.5 ng in plasma (d)
was assessed by magnetic immunoprecipitation and SDS-PAGE
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8). Combined, this indicated that anti-PA levels on the beads
were sufficient to capture LTx and excess non-complexed
PA63. Thus, PA did not saturate the beads at these levels.
Furthermore, much less material is used for LTx calibrators.
The highest standard is at 24 ng/mL with only 50 μL used for
analysis. In summary, anti-PAwas suitable for purification of
LTx and the excess PA63 did not interfere with its purification.
Catalytic activity and quantification of LTx
LTx activity is quantified by cleavage of a peptide substrate
yielding two products (Fig. 3a). MALDI-TOF MS of a repre-
sentative positive reaction show the substrate at 2804.2 m/z,
two products at 1232.8 and 1589.8 m/z and ISTD peptide
peaks at 1239.8 and 1596.8 m/z, respectively (Fig. 3b).
Narrowing the x-axis shows the isotopic detail of the CT-
product and ISTD. The CT isotopic area divided by the CT-
ISTD area yields the area ratio that is directly proportional to
the amount of LTx present. For a negative reaction processed
from the plasma blank only the substrate and ISTD peaks are
present (Fig. 3c). Area ratios were plotted versus concentra-
tion and both axes were log10 transformed generating a sig-
moidal curve. Quantitative accuracy was optimal using 5PL
regression with robust weighting. Custom visual basic pro-
grams integrated MS peaks and applied the 5PL fits to quan-
tify standards and samples (Fig. 3d).
Fig. 3 ID-MALDI-TOF MS of LTx catalytic activity and quantification.
The LTx substrate peptide sequence shown in standard amino acid codes
except for non-standard amino acid norleucine depicted as an X.
Magnetic-affinity-purified LTx hydrolyzes the LF peptide substrate
between the p1 proline and p1' tyrosine, yielding two smaller peptides
(a). The cleavage reaction is mixed with ISTD peptides (+7 m/z) and
analyzed by ID-MALDI-TOF MS. Spectra show a positive reaction
with LTx in plasma (b) and negative reaction without LTx in plasma
(c). Output for the 5PL regression generated by custom visual basic
software for an 18-h reaction. The orange line indicates the estimated
LOD (three times the plasma blank area ratio) for each analysis (c).
Linearity of LTx quantification for 25 independent analyses of
standards levels showing means and SD (error bars) for 2- and 18-h
reactions (e)
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LTx method validation
Performance criteria were determined with 25 independent
analyses of LTx standards/QC sets. Means, standard devia-
tions (SD), %error, and %CV are shown for each level and
reaction time (Table 1). Recommended accuracy of ≤20 %er-
ror and precision of ≤20 and ≤15 %CV for the ULOQ and
≤25 %CV for the LLOQ defined the quantitative range [29,
33]. Interday accuracy for 2-h reactions was 0.1–9.8 %error
from S1 to S12 ng/mL and precision was 3.7–14 %CV from
S1 to S10. S11, at 24 %CV, met the recommendation for
LLOQ. Therefore, the optimal quantitative range for 2-h re-
actions was S1–S11, with the LLOQ at 0.049 ng/mL. For 18-h
reactions, accuracy and precision, respectively, were 0.2–
13 %error for S5–S14 and 4.2–12 %CV for S5–S12. S13
(0.012 ng/mL) with 25 %CV, was acceptable for the 18-h
LLOQ. The detection limit calculated from 30 independent
analyses of low plasma standards was 0.033 ng/mL and
0.0074 ng/mL for the 2- and 18-h reaction times, respectively.
The calculated mean concentrations plotted versus expected
concentration showed linear regressions with slopes near 1,
0.96 for 2-h, and 1.06 for 18-h reactions, and r2≥0.991 for
both 2- and 18-h reactions (Fig. 3e). Mean values for 2- and
18-h reactions were precisely overlaid at the universal levels.
Precision from 25 independent QC analyses was 9.9 and
7.2 %, respectively, for QCH and QCM for the 2-h reaction
time and 6.3 and 9.0 %, respectively for QCM and QCL for
the 18-h reaction time (Table 1).
Extraction recoveries could not be properly assessed be-
cause activity of LF was higher when bound by PA63 and
anti-PA-MB. Area ratios obtained from reactions were much
lower for 0.5 ng LF alone (1.4±0.02), compared with 0.5 ng
LF in complex as LTx (20±1) and LTx extracted by anti-PA
(22±0.3). This implied recoveries of >100 %.
Specificity was 100%. There were no false positives for 100
plasma samples from North American donors and 41 serum
samples from other infections. Sensitivity was 100 % with
LTx measured in all infected subjects, three documented inha-
lation anthrax cases, and 24 rhesus macaques [26, 27, 31, 34].
There was no observable interference from other anthrax
toxins and accuracy was good with low error of 0.8–12.7 %
for samples covering three orders of magnitude (Table 2). This
included 50 ng PA83 and EF toxins, 667-fold excess at the
lowest LTx level. Inclusion of 50 ng/mL free LF contributed
to higher LTx as expected since it was able to bind the excess
free PA63 in the LTx sample.
Table 1 Mean, SD, accuracy (% error), precision (%CV), and
analytical ranges (bold font) for LTx standards, plasma blank (PBL),
and quality control samples (QCs), for 2- and 18-h reactions analyzed
over 25 days. Standard levels with ≤20 % error, ≤20 %CV for middle
range, ≤15 % CV (ULOQ), and ≤25 % CV (LLOQ) are indicated in
italics. Limits of detection (LOD) were calculated as described
LTx standard Expected (ng/mL) 2-h reaction 18-h reactions
Observed (ng/mL) SD %error CV (%) Observed (ng/mL) SD %error CV (%)
S1 24.3 22.9 1.78 5.4 7.8 14.0 4.3 42 31
S2 14.6 16.0 1.47 9.8 9.2 12.9 1.9 11 15
S3 9.7 9.55 0.56 1.5 5.9 11.6 2.6 20 23
S4 4.85 4.81 0.24 0.9 4.9 5.89 1.2 21 20
S5 2.43 2.52 0.093 4.1 3.7 2.63 0.31 8.3 12
S6 0.97 0.932 0.042 3.9 4.5 0.890 0.051 8.2 5.7
S7 0.485 0.485 0.018 0.1 3.7 0.462 0.019 4.8 4.2
S8 0.243 0.254 0.019 4.8 7.4 0.249 0.015 2.7 6.1
S9 0.146 0.156 0.016 7.0 11 0.155 0.010 6.7 6.4
S10 0.097 0.093 0.013 4.0 14 0.097 0.0071 0.2 7.3
S11 0.049 0.045 0.011 7.2 24 0.050 0.0050 2.1 10
2-h LOD 0.033 NA NA NA
S12 0.024 0.024 0.0083 0.6 34 0.024 0.0029 0.4 12
S13 0.012 0.014 0.0067 18 47 0.011 0.0027 13 25
18-h LOD 0.0075 NA NA NA
S14 0.0049 0.009 0.0078 83 88 0.0054 0.0039 12 72
S15 0.0024 0.007 0.0074 185 107 0.0035 0.0014 45 39
PBL 0 0.0019 0.0041 NA 213 0.00037 0.0010 NA 278
QCH 5.82 5.29 0.52 9.1 9.9 NA NA NA NA
QCM 0.582 0.547 0.039 6.0 7.2 0.528 0.033 9.3 6.3
QCL 0.0582 NA NA NA NA 0.055 0.005 5.3 9.0
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Matrix-dependent accuracy was assessed because serum
and plasma samples may have different components released
during processing that influence LTx activity. LTx levels mea-
sured in the serum samples (2.6±0.28 ng/mL) were similar to
plasma (2.4±0.17 ng/mL) for a 2-h reaction but were higher in
serum (3.1±0.42 ng/mL) than plasma (2.6±0.31 ng/mL) after
18 h. The mean %error in calculated value from the expected
2.5 ng/mL for 2 and 18 h combined was lower for plasma
samples at 7.7±6.8 % compared with serum at 17±14 % sug-
gesting that factors present in serum may reduce accuracy and
produce more variability in LTx activity.
Serum and plasma matrices were also evaluated for artifi-
cial cleavage of PA83 to PA63 by serum clotting cascade
proteases which would form LTx in the presence of LF. No
LTx was detected in serum or plasma spiked with PA83 and
LF at 5 and 2.5 ng/mL, respectively. In contrast, PA63 and LF
spiked together resulted in significant formation of complex in
both serum (1.8±0.16 ng/mL) and plasma (2.0±0.074 ng/
mL), with plasma LTxmeasured higher than serum. This dem-
onstrated that no measureable conversion of PA83 to PA63
occurred in serum or plasma under these conditions.
The interference of AIG (Cangene Corp, Canada) on LTx
quantification was assessed by spiking standards, QCs, plasma
blank, and an infection sample with therapeutic levels of AIG
(200 μg/mL anti-PA IgG). LTx measured was lower with AIG
compared with samples without AIG (Table 3). Overall, accu-
racy was high with only 9.4±8.0 % error without AIG and was
lower with AIG at 40±20 % error. However, accuracy was
better for the higher AIG-spiked standards, 11–24 % error
(S2–S4) and was reduced in lower standards and all QCs, rang-
ing from 34 to 70% error (S5–S12, QCH,M, L). LTxwith AIG
was detected as low as the S12 standard (0.024 ng/mL), though
it was quantified lower at 0.014±0.007 ng/mL. LTx in a clinical
sample was similar at 93±4.7 ng/mL with AIG compared with
that without AIG (88±2.6 ng/mL), indicating no interference
by AIG in this sample (Table 3).
Interference of LTx detection by antimicrobial treatment
was assessed in six rhesus macaques and three clinical cases
[26, 27, 31, 34]. Pre- and post-antimicrobial treatment LTx
levels were determined for all subjects except one for which
a pre-treatment sample was not available (Table 4). Pre-
treatment LTx levels were 2.3–280 ng/mL. LTx was detected
post-treatment in all subjects. Latest post-treatment LTx was
low in the survivors (2–8 days post-treatment), at 0.012–
0.096 ng/mL, and was higher in two non-surviving rhesus
macaques, 8.6 and 8.7 ng/mL. In animal R050003, the higher
post-treatment LTx appeared to be due to a short treatment
interval (36 h) and in animal 04208 to higher pre-treatment
LTx (280 ng/mL).
LTx detection in rhesus macaques during inhalation anthrax
Two female rhesus macaques, 16N and 89N, were exposed by
aerosol inhalation to 248 and 264 LD50 B. anthracis Ames
spores, respectively. Both animals survived 5 days post-expo-
sure. Both were positive for culture, pagA PCR, and LTx by
36 h and remained positive (Table 5). Earliest LTx levels were
low, 0.24 and 0.10 ng/mL for 16N and 89N, respectively. An-
imal 16N increased almost 100-fold from 36 to 72 h to 21 ng/
mL, declined to 5.4 ng/mL at 96 h, then increased >2000-fold at
120 h to 12,100 ng/mL. Animal 89N increased 10-fold from 36
to 48 h to 1.02 ng/mL, remained stable at 72 h, increased 10-
fold at 96 h (11.5 ng/mL), then 100-fold at 120 h (1150 ng/mL).
Comparison of LTx with total LF (free LF+LTx) showed
that LF was first detected in animal 16N and 89N at 18 and
24 h post-exposure, respectively, 18 and 12 h prior to LTx,
culture, and PCR (Table 5). At 36 h, LF was 7.5–22 times
higher than LTx, demonstrating a majority of free LF in the
earliest stages of infection. However, at the terminal stage,
LTx increased and was 100 % of the total LF for 16N and
60 % for 89N. In summary, LTx was detected early and in-
creased to become the dominant form of LF in late infection.
Table 2 Accuracy (%error) of LTx quantitation in the presence of other anthrax toxins, PA83, LF, and EF
LTx (ng/mL) PA83 (ng/mL) LF (ng/mL) EF (ng/mL) Mean±SD (2 h) Mean±SD (18 h) %error (2 h) %error (18 h)
LTx-1 7.5 – – – 8.2±0.31 8.5
LTx-2 7.5 50 – – 8.4±0.17 11.5
LTx-3 7.5 – 50 – 22±0.19 NA
LTx-4 7.5 – – 50 7.7±0.15 3.3
LTx-5 0.75 – – – 0.80±0.022 0.71±0.023 6.1 5.9
LTx-6 0.75 50 – – 0.84±0.011 0.74±0.011 12.3 0.8
LTx-7 0.75 – 50 – 8.5±0.12 8.2±0.38 NA NA
LTx-8 0.75 – – 50 0.76±0.03 0.66±0.021 1.2 11.8
LTx-9 0.075 – – – <LOD 0.083±0.0035 9.9
LTx-10 0.075 50 – – <LOD 0.085±0.0012 12.7
LTx-11 0.075 – 50 – 0.98±0.018 0.86±0.032 NA
LTx-12 0.075 – – 50 <LOD 0.076±0.0022 1.8
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Discussion
Here, we report development and validation of a method that
quantifies LTx complex. Combining the strategy that provided
sensitive LF detection with selective PA purification allowed
sensitive measurements for LTx. It is more sensitive, 0.033 ng/
mL for 2 h and 0.0075 ng/mL for the 18-h reaction, and more
accurate than other methods for PA [2–9]. The two reaction
times provide quantitation over a large dynamic range, from
24 to 0.0012 ng/mL, which is extended even higher with sam-
ple dilutions, as seen with the highest infection sample at 12,
100 ng/mL. With a 2-h reaction, the method achieves a rela-
tively fast 4-h total time to detection and is still extremely
sensitive comparedwith other methods. The longer incubation
time improves the detection limit 4.7-fold and assists in
confirming low-level positives, ruling out negatives and con-
firmation of low-level quantification.
Accuracy within the defined quantifiable ranges was high
(0.1–13 % error) under all conditions in plasma, including
those with other toxins expected to be present during infec-
tion. In a less optimal matrix such as serum, accuracy was
acceptable (17±14 % error) but had greater variability com-
pared with plasma (7.7±6.8 %). This may be due to serum
collection that can include varying degrees of neutrophil lysis
and release of defensins which are reported to decrease LF
activity [35]. Serum preparation may also initiate the clotting
cascade that releases proteases that could artificially cleave
and activate PA83 to PA63, artificially increasing LTx mea-
sured. This was not observed when PA83 was spiked along
with LF in either serum or plasma. There was no consistency
in whether LTx measured in serum was increased or de-
creased. When spiked in various donor samples, LTx was
higher in serum than plasma. When spiked with PA63 and
LF separately, LTx was lower in serum than plasma. For
LTx quantification, either matrix can be used but plasma is
preferred.
Three steps, antibody purification, enzymatic activity, and
mass spectrometric detection of specific cleavage products,
combine to minimize cross reactivity. Taken together, it pro-
vided specificity of 100%. Sensitivity was also 100%with no
false negatives for 3 humans and 24 rhesus macaque inhala-
tion infections. Though the human inhalation anthrax case
numbers for which samples were available was low, the sen-
sitivity was supported by the positive results in 24 inhalation-
infected rhesus macaques and was further supported by posi-
tive results following antibiotic treatment in all nine available
treated subjects and as long as 8 days post-antibiotics in one
case [26]. This is also important in terms of diagnostic
Table 3 Effect of AIG (200 μg/mL) on LTx quantification
Level Expected (ng/mL) No AIG AIG
LTx (ng/mL) SD %error LTx (ng/mL) SD %error
S1 24.3 22 5.20 9.0 17 0.79 32
S2 14.6 13 2.84 10 13 2.3 11
S3 9.7 11 1.34 16 8.5 2.8 12
S4 4.85 4.1 1.68 17 3.7 1.8 24
S5 2.43 2.6 0.108 8.1 1.6 0.68 35
S6 0.97 0.87 0.008 10 0.41 0.033 57
S7 0.485 0.48 0.014 1.9 0.20 0.014 58
S8 0.243 0.26 0.020 5.3 0.14 0.042 41
S9 0.146 0.16 0.030 11 0.096 0.029 34
S10 0.097 0.099 0.0035 2.5 0.042 0.012 57
S11 0.049 0.049 0.0060 0.03 0.016 0.0080 68
S12 0.024 0.018 0.0008 24 0.014 0.0071 42
S13 0.012 0.013 0.0017 9.0 <LOD NA NA
S14 0.0049 <LOD NA NA <LOD NA NA
S15 0.0024 <LOD NA NA <LOD NA NA
Plasma BL 0 <LOD NA NA <LOD NA NA
QCH 5.82 7.4 1.2 28 3.1 0.029 47
QCM 0.582 0.54 0.021 7.4 0.29 0.051 51
QCL 0.0582 0.06 0.001 0.21 0.02 0.010 70
Sample 88 88 2.6 0.23 93 4.7 5.7
Mean±SD 9.4±8.0 40±20
Mean, SD, and accuracy (%error) for standards, QCs, and a clinical anthrax sample are shown
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potential, since antibiotic use renders methods that depend on
the organism such as culture and PCR, negative, usually with-
in 24 h following treatment initiation.
This method may be useful for evaluation of the efficacy of
PA-targeted therapeutics such as AIGIV. There was higher
error of 40±20 % from AIG at LTx levels below 1 ng/mL,
which was similar to that seen previously for a TRF PA assay
with a 50 % reduction in signal for a 5.4-fold ratio of AIG to
PA [5]. However, LTx was still detectable at low levels,
0.024 ng/mL, even with extreme excesses of 200 μg/mL
anti-PA IgG. Thus, any negative impact on detection was
small in context of the detection limit. There was no interfer-
ence in an AIG-spiked clinical sample. Though it reduces the
ability to accurately measure LTx at lower levels, in vitro, it is
expected that during treatment, AIG binding PA63 would ac-
tually reduce circulating levels in vivo. The in vitro interfer-
ence could be a measure of in vivo LTx clearance. The utility
of this method for AIG will be validated further.
Previous reports of freely circulating LTx complex in ter-
minal samples in rabbits, guinea pigs, and monkeys [18, 20,
36], were confirmed in this study in rhesus macaques. The
sensitivity of this method allowed the first detection of cata-
lytically active LTx early and throughout infection. That LTx
increases to high levels in late infection, suggests its impor-
tance in the process of infection and rapid death. In all, these
results demonstrated the importance of LTx as a diagnostic
Table 4 Impact of antimicrobial agents on LTx detection during
inhalation anthrax in rhesus macaques treated with Ciprofloxacin
(Cipro) commencing at the time point indicated 48 or 72 h post-
challenge (PC) and in human clinical cases treated with antimicrobial
agents following hospitalization








RM (R050003) NS (72 h) Cipro 48 h PC 14 36 h PC 8.6 36 h (LA)
RM (04208) NS (6 days) Cipro 48 h PC 280 48 h PC 8.7 72 h (LA)
RM (03E062 S Cipro 48 h PC 7.6 48 h PC 0.095 48 h
RM (04E067) S Cipro 48 h PC 12 48 h PC 0.096 72 h
RM (0412) S Cipro 72 h PC 8.3 72 h PC 0.072 72 h
RM (04E083) S Cipro 72 h PC 2.3 72 h PC 0.12 72 h
Human (2006) S At admission 2.6 3DPO 0.012 8 days
Human (2008) NS At admission NA NA 0.018 6 days (FA)
Human (2011) S At admission 2.3 2DPO 0.023 68 h
The LTx results are given for samples obtained prior to antimicrocrobial treatment (Pre-Abx) and the last available sample positive (post-Abx)
NA not available, NS non-survival, S survived, LA latest available post-antibiotic sample, FA first available, Abx antimicrobials/antibiotics, DPO days
post-symptom onset
Table 5 Comparison of LTx quantification with other anthrax diagnostic biomarkers, bacteremia (bact), pagA PCR, and total LF, over the course of
inhalation anthrax in two rhesus macaques
Time PC 16N 89N
Bact/PCR LTx Total LF Bact/PCR LTx Total LF
−30 days – <LOD <LOD – <LOD <LOD
12 h – NT <LOD – NT <LOD
18 h – NT 0.026 – NT <LOD
24 h – <LOD 0.13±0.016 – NT 0.049±0.012
30 h – <LOD 0.69±0.044 – <LOD 0.32±0.061
36 h ±/+ 0.24±0.041 1.8±0.16 +/+ 0.10±0.012 2.2±0.51
48 h +/+ 0.76±0.074 13±1.0 +/+ 1.02±0.039 30±1.5
72 h +/+ 21±0.54 53±3.7 +/+ 1.25±0.079 20±0.64
96 h NA 5.4±1.4 22±0.35 NA 12±1.5 72±2.7
120 h +/+ 12,100±1270 12,200±670 +/+ 1150±170 1930±44
Bact is positive (+) for ≥6 colonies in the primary streak, low positive (±) for one to five colonies, negative (−) for no colonies. Qualitative pagA PCR is
positive (+) or negative (−). LOD=0.0075 ng/mL for LTx and 0.005 ng/mL for total LF. All samples with available volumes were analyzed in duplicate
at minimum and at one or more dilutions
PC post-challenge, NA not analyzed
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and therapeutic target. The method described should provide a
sensitive, fast, accurate tool for anthrax toxin detection and
evaluation of PA-directed therapeutics.
Disclaimer The findings and conclusions in this report are those of the
authors and do not necessarily represent the views of the Centers for
Disease Control and Prevention
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